In preclinical models, AB-729 provides deep and durable reduction of HBsAg and the other HBV proteins that is superior to first generation LNP-based RNAi agents.

We are developing a second-generation RNAi agent, AB-729, a subcutaneously-administered GalNAc conjugate. AB-729 targets HBV replication and antigen production and has demonstrated potent and durable reductions in HBsAg in both in vitro and in vivo preclinical models. This agent is expected to enter clinical trials in 2Q 2019 and will subsequently be combined with AB-506 and approved nucleoside analogs with the goal of increasing cure rates in HBV patients.